BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies |
||||
Company |
Ticker
|
Current Price
(May 17, 2005) |
Last Price
(May 10, 2005) |
% Change
|
Agilent |
A
|
22.48
|
21.86
|
2.84
|
Applied Biosystems
|
ABI
|
22.45
|
22.45
|
0.00
|
BD |
BDX
|
58.96
|
59.17
|
-0.35
|
Beckman |
BEC
|
68.1
|
66.38
|
2.59
|
Bio-Rad |
BIO
|
51.92
|
52.58
|
-1.26
|
Bruker |
BRKR
|
3.99
|
3.54
|
12.71
|
GE |
GE
|
36.8
|
35.83
|
2.71
|
Harvard Bio |
HBIO
|
2.9
|
3.4
|
-14.71
|
Invitrogen |
IVGN
|
78.34
|
76.52
|
2.38
|
Molecular Devices |
MDCC
|
18.29
|
18.81
|
-2.76
|
PerkinElmer |
PKI
|
18.57
|
18.88
|
-1.64
|
Sigma |
SIAL
|
59.37
|
59.54
|
-0.29
|
Stratagene |
STGN
|
8.64
|
9.19
|
-5.98
|
Thermo |
TMO
|
26.8
|
26.15
|
2.49
|
Waters |
WAT
|
38.81
|
40.03
|
-3.05
|
Index Average |
34.43
|
34.29
|
0.41
|
Bruker Shares Lead Winners Thanks to $1.1M in CEO's Insider Buys
Shares in Bruker climbed 12.71 percent during the five-day trading period ended Tuesday, making it the leading gainer for the BCW companies in a week in which the Index grew at an anemic .41 percent and losers outnumbered gainers.
Bruker's stock has been climbing since May 10 when CEO Frank Laukien launched a buying spree that cost him more than $1.1 million and earned him 277,430 shares.
According to Insidercow.com, which tracks insider trading at public companies, Laukien bought the stock at prices between $3.60 and $3.00 per share between May 10 and May 17.
Leading the losers last week was Harvard Bio, whose shares tanked 14.71 percent soon after the company released its annual 10-Q with the SEC. The company has lost more than one-third of its market cap since early March.